Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CABA

Cabaletta Bio (CABA)

Cabaletta Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CABA
DateTimeSourceHeadlineSymbolCompany
12:52PMiHub NewswireFeaturedCannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA
03/21/20247:00AMGlobeNewswire Inc.Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CABACabaletta Bio Inc
03/20/20247:00AMGlobeNewswire Inc.Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic SclerosisNASDAQ:CABACabaletta Bio Inc
03/04/20245:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CABACabaletta Bio Inc
03/04/20245:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CABACabaletta Bio Inc
03/04/20245:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CABACabaletta Bio Inc
03/04/20245:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CABACabaletta Bio Inc
03/04/20245:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CABACabaletta Bio Inc
02/27/20248:00AMGlobeNewswire Inc.Cabaletta Bio to Participate in Upcoming Investor Conferences in MarchNASDAQ:CABACabaletta Bio Inc
02/14/20249:20AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CABACabaletta Bio Inc
02/13/20246:47PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CABACabaletta Bio Inc
02/01/20244:36PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CABACabaletta Bio Inc
02/01/20244:30PMGlobeNewswire Inc.Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of MyositisNASDAQ:CABACabaletta Bio Inc
01/31/20248:00AMGlobeNewswire Inc.Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:CABACabaletta Bio Inc
01/19/20246:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CABACabaletta Bio Inc
01/08/20247:11AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CABACabaletta Bio Inc
01/08/20247:00AMGlobeNewswire Inc.Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic SclerosisNASDAQ:CABACabaletta Bio Inc
01/02/20248:00AMGlobeNewswire Inc.Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CABACabaletta Bio Inc
12/19/20238:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CABACabaletta Bio Inc
11/29/20236:18AMIH Market NewsAmazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and MoreNASDAQ:CABACabaletta Bio Inc
11/28/20234:30PMGlobeNewswire Inc.Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:CABACabaletta Bio Inc
11/28/20232:59PMDow Jones NewsCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNASDAQ:CABACabaletta Bio Inc
11/21/20234:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CABACabaletta Bio Inc
11/20/20234:16PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CABACabaletta Bio Inc
11/09/20237:24AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CABACabaletta Bio Inc
11/09/20237:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CABACabaletta Bio Inc
11/09/20237:00AMGlobeNewswire Inc.Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CABACabaletta Bio Inc
11/06/20238:15AMBusiness WireCellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle PlatformNASDAQ:CABACabaletta Bio Inc
11/06/20237:55AMDow Jones NewsCabaletta Bio Gets FDA OK to Study CABA-201 in Generalized Myasthenia GravisNASDAQ:CABACabaletta Bio Inc
11/06/20237:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CABACabaletta Bio Inc
 Showing the most relevant articles for your search:NASDAQ:CABA